Albumin dialysis: An update

Current Opinion in Nephrology and Hypertension

Volumn 16, Issue 6, 2007, Pages 589-595

  Mitzner, Steffen R ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Acute liver failure; Albumin dialysis; Liver support; Molecular adsorbent recirculating system

Indexed keywords

ALBUMIN DIALYSIS; CLINICAL STUDY; HEMODYNAMICS; HUMAN; LIVER FAILURE; LIVER REGENERATION; LIVER SUPPORT; LIVER TRANSPLANTATION; MEDICAL CARE; PRIORITY JOURNAL; REVIEW; SAFETY; SURVIVAL;

ALBUMINS; HUMANS; LIVER FAILURE; LIVER REGENERATION; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 37349024688     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3282f0abdb     Document Type: Review

References (83)

1. Mitzner SR, Stange J, Klammt S, et al. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol 2001; 12 (Suppl 17):S75-S82.
2. Covic A, Maftei ID, Gusbeth-Tatomir P. Acute liver failure due to leptospirosis successfully treated with MARS (molecular adsorbent recirculating system) dialysis. Int Urol Nephrol 2007; 39:313-316. The first report about the use of liver support in leptospirosis-associated ALF.
3. Penafiel A, Devanand A, Tan HK, Eng P. Use of molecular adsorbent recirculating system in acute liver failure attributable to dengue hemorrhagic fever. J Intens Care Med 2006; 21:369-371. The first report on the use of liver support in dengue haemorrhagic fever-associated ALF.
4. Tsai SH, Chang HM, Hsieh CB, et al. Acute fulminant hepatitis B in a patient with diabetic nephropathy treated successfully with concomitant lamivudine and molecular adsorbents recirculating system. J Infect 2006; 53:e19-e23.
5. Pichon N, François B, Chevreuil C, Gaulier JM. Albumin dialysis: a new therapeutic alternative for severe diltiazem intoxication. Clin Toxicol (Phil) 2006; 44:195-196. The first report about the use of liver support in calcium antagonist intoxication.
6. Lee KH, Lee MK, Sutedja DS, Lim SG. Outcome from molecular adsorbent recycling system (MARS) liver dialysis following drug-induced liver failure. Liver Int 2005; 25:973-977.
7. Lionte C, Sorodoc L, Simionescu V. Successful treatment of an adult with Amanita phalloides-induced fulminant liver failure with molecular adsorbent recirculating system (MARS). Rom J Gastroenterol 2005; 14:267-271.
8. Braun C, Birck R, Singer MV, et al. Life-threatening intoxication with methylene bis(thiocyanate): clinical picture and pitfalls: a case report. BMC Emerg Med 2006; 6:5. The first report about the use of liver support in thiocyanate intoxication.
9. Hetz H, Faybik P, Berlakovich G, et al. Molecular adsorbent recirculating system in patients with early allograft dysfunction after liver transplantation: a pilot study. Liver Transpl 2006; 12:1357-1364. A Pathfinder study for the future investigation of the role of liver support in post-transplant liver dysfunction.
10. Inderbitzin D, Muggli B, Ringger A, et al. Molecular absorbent recirculating system for the treatment of acute liver failure in surgical patients. J Gastrointest Surg 2005; 9:1155-1161.
11. El Banayosy A, Kizner L, Schueler V, et al. First use of the molecular adsorbent recirculating system technique on patients with hypoxic liver failure after cardiogenic shock. ASAIO J 2004; 50:332-337.
12. Guo LM, Liu JY, Xu DZ, et al. Application of molecular adsorbents recirculating system to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome. Liver Int 2003; 23 (Suppl 3):16-20.
13. Tiruvoipati R, Moorthy T, Balasubramanian SK, et al. Extracorporeal membrane oxygenation and extracorporeal albumin dialysis in pediatric patients with sepsis and multiorgan dysfunction syndrome. Int J Artif Organs 2007; 30:227-234. The first report about the combined use of extracorporeal membrane oxygenation and MARS in children.
14. Kurtovic J, Boyle M, Bihari D, Riordan SM. An Australian experience with the molecular adsorbents recirculating system (MARS). Ther Apher Dial 2006; 10:2-6.
15. Auth MK, Kim HS, Beste M, et al. Removal of metabolites, cytokines and hepatic growth factors by extracorporeal liver support in children. J Pediatr Gastroenterol Nutr 2005; 40:54-59.
16. Trittenwein G, Boigner H, Mostafa G, et al. Bridging to transplantation in acute liver failure in a 7-month-old infant. Wien Klin Wochenschr 2006; 118:298-301. One of the first reports describing the safe bridging of an infant to liver transplantation.
17. Debray D, Yousef N, Durand P. New management options for end-stage chronic liver disease and acute liver failure: potential for pediatric patients. Paediatr Drugs 2006; 8:1-13. A review putting MARS into the context of current therapeutic approaches towards liver failure in infants and children.
18. Tissières P, Sasbón JS, Devictor D. Liver support for fulminant hepatic failure: is it time to use the molecular adsorbents recycling system in children? Pediatr Crit Care Med 2005; 6:585-591.
19. Nadalin S, Heuer M, Wallot M, et al. Paediatric acute liver failure and transplantation: the University of Essen experience. Transpl Int 2007; 20:519-527. One of the largest series on the use of liver support in paediatric cases of liver failure.
20. Liu YH, Wang Y, Yu LX, et al. Artificial liver support molecular adsorbents recirculating system therapy as a bridge to re-transplantation in two cases of long anhepatic duration. Hepatobiliary Pancreat Dis Int 2004; 3:316-317.
21. Koivusalo AM, Vakkuri A, Höckerstedt K, Isoniemi H. Experience of MARS therapy with and without transplantation in 101 patients with liver insufficiency. Transplant Proc 2005; 37:3315-3317.
22. Camus C, Lavoué S, Gacouin A, et al. Molecular adsorbent recirculating system dialysis in patients with acute liver failure who are assessed for liver transplantation. Intens Care Med 2006; 32:1817-1825. Together with ref. [21] this is the largest series of MARS in liver transplant candidates. It reports a significant recovery of native liver function.
23. Yuan JZ, Ye QF, Zhao LL, et al. Preoperative risk factor analysis in orthotopic liver transplantation with pretransplant artificial liver support therapy. World J Gastroenterol 2006; 12:5055-5059. The first study to report the impact of MARS treatment on the preoperative risk factors of liver transplant related to transplant-free and post-transplant survival.
24. Choi JY, Bae SH, Yoon SK, et al. Preconditioning by extracorporeal liver support (MARS) of patients with cirrhosis and severe liver failure evaluated for living donor liver transplantation: a pilot study. Liver Int 2005; 25:740-745.
25. Doria C, Mandalá L, Scott VL, et al. Fulminant hepatic failure bridged to liver transplantation with a molecular adsorbent recirculating system: a single-center experience. Dig Dis Sci 2006; 51:47-53. A very clear study reporting the impact of MARS on the course and outcome in ALF.
26. Gaspari R, Avolio AW, Zileri Dal Verme L, et al. Molecular adsorbent recirculating system in liver transplantation: safety and efficacy. Transplant Proc 2006; 38:3544-3551. A single-centre series reporting the safety and efficacy of MARS in liver transplantation.
27. Wai CT, Lim SG, Aung MO, et al. MARS: a futile tool in centres without active liver transplant support. Liver Int 2007; 27:69-75. One of the few reports describing a mixed population of patients without recovery of native function.
28. Chiu A, Chan LM, Fan ST. Molecular adsorbent recirculating system treatment for patients with liver failure: the Hong Kong experience. Liver Int 2006; 26:695-702.
29. Stefoni S, Colì L, Bolondi L, et al. Molecular adsorbent recirculating system (MARS) application in liver failure: clinical and hemodepurative results in 22 patients. Int J Artif Organs 2006; 29:207-218. A thorough description of a single-centre case series of MARS treatments in different forms of liver failure.
30. Novelli G, Rossi M, Pretagostini M, et al. One hundred sixteen cases of acute liver failure treated with MARS. Transplant Proc 2005; 37:2557-2559.
31. Heemann U, Treichel U, Loock J, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002; 36:949-958.
32. Di Campli C, Santoro MC, Gaspari R, et al. Catholic university experience with molecular adsorbent recycling system in patients with severe liver failure. Transplant Proc 2005; 37:2547-2550.
33. Stadlbauer V, Krisper P, Beuers U, et al. Removal of bile acids by two different extracorporeal liver support systems in acute-on-chronic liver failure. ASAIO J 2007; 53:187-193. The first study describing differences in the removal of hydrophobic bile acids between MARS and Prometheus.
34. Sen S, Davies NA, Mookerjee RP, et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl 2004; 10:1109-1119.
35. Kurtovic J, Boyle M, Bihari D, et al. Nitric-oxide-lowering effect of terlipressin in decompensated cirrhosis: comparison to the molecular adsorbent recirculating system and correlation with clinical status. Eur J Gastroenterol Hepatol 2004; 16:1335-1338.
36. Laleman W, Wilmer A, Evenepoel P, et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2006; 10:R108. The first study describing the superiority of MARS over Prometheus with regard to nitric oxide removal and haemodynamic improvements in AoCLF.
37. Isoniemi H, Koivusalo AM, Repo H, et al. The effect of albumin dialysis on cytokine levels in acute liver failure and need for liver transplantation. Transplant Proc 2005; 37:1088-1090.
38. Di Campli C, Zocco MA, Gaspari R, et al. The decrease in cytokine concentration during albumin dialysis correlates with the prognosis of patients with acute on chronic liver failure. Transplant Proc 2005; 37:2551-2553.
39. Ilonen I, Koivusalo AM, Höckerstedt K, Isoniemi H. Albumin dialysis has no clear effect on cytokine levels in patients with life-threatening liver insufficiency. Transplant Proc 2006; 38:3540-3543.
40. Stadlbauer V, Krisper P, Aigner R, et al. Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure. Crit Care 2006; 10:R169. A report comparing the cytokine removal of MARS with that of Prometheus.
41. Eefsen M, Rasmussen A, Wulf HC, et al. Erythropoietic protoporphyria and pretransplantation treatment with nonbiological liver assist devices. Liver Transpl 2007; 13:655-657. The first report describing the use of liver support in erythropoietic protoporphyria.
42. McGuire BM, Bloomer JR. Use of extracorporeal albumin dialysis for erythropoietic protoporphyria. Liver Transpl 2007; 13:639-640.
43. Vogelsinger H, Joannidis M, Kountchev J, et al. Pharmacokinetics of liposomal amphotericin B during extracorporeal albumin dialysis. Artif Organs 2006; 30:118-121. The first report investigating amphotericin B removal by albumin dialysis.
44. Klammt S, Mitzner S, Stange J, et al. Albumin-binding function is reduced in patients with decompensated cirrhosis and correlates inversely with severity of liver disease assessed by model for end-stage liver disease. Eur J Gastroenterol Hepatol 2007; 19:257-263. A description of a new test that might be very helpful in assessing liver failure patients for their need for albumin dialysis.
45. Schmidt LE, Wang LP, Hansen BA, Larsen FS. Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: a prospective controlled trial. Liver Transpl 2003; 9:290-297.
46. Sen S, Mookerjee RP, Cheshire LM, et al. Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. J Hepatol 2005; 43:142-148.
47. Mitzner S, Loock J, Peszynski P, et al. Improvement in central nervous system functions during treatment of liver failure with albumin dialysis MARS: a review of clinical, biochemical, and electrophysiological data. Metab Brain Dis 2002; 17:463-475.
48. Sen S, Rose C, Ytrebø LM, et al. Effect of albumin dialysis on intracranial pressure increase in pigs with acute liver failure: a randomized study. Crit Care Med 2006; 34:158-164. The first controlled animal study investigating the impact of MARS on intracranial pressure. It contains brain water and brain ammonia measurements that help explain the significantly lower intracranial pressure level in the MARS group.
49. Mitzner SR. Drain the brain: albumin dialysis for intracranial hypertension. Crit Care Med 2006; 34:254-255. A current review of the clinical knowledge regarding the impact of MARS on intracranial pressure.
50. Saich R, Collins P, Ala A, et al. Benign recurrent intrahepatic cholestasis with secondary renal impairment treated with extracorporeal albumin dialysis. Eur J Gastroenterol Hepatol 2005; 17:585-588.
51. Schött U, Henriksson BA, Hansson P. Exertional heat stroke caused severe hepatic and renal failure: liver dialysis by means of MARS tested for the first time in this setting [in Swedish]. Lakartidningen 2006; 103:2050-2053. The first report on the use of liver support in heat stroke-associated liver failure.
52. Mitzner SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6:277-286.
53. Cárdenas A, Ginès P. Therapy insight: management of hepatorenal syndrome. Nat Clin Pract Gastroenterol Hepatol 2006; 3:338-348. A current review putting MARS into the context of other HRS therapies.
54. Moreau R, Lebrec D. Diagnosis and treatment of acute renal failure in patients with cirrhosis. Best Pract Res Clin Gastroenterol 2007; 21:111-123. A current review putting MARS into the context of other HRS therapies.
55. Wong F. Drug insight: the role of albumin in the management of chronic liver disease. Nat Clin Pract Gastroenterol Hepatol 2007; 4:43-51. A current review discussing the role of albumin and MARS in the context of liver failure therapy.
56. Bellmann R, Graziadei IW, Feistritzer C, et al. Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis. Liver Transpl 2004; 10:107-114.
57. Montero JL, Pozo JC, Barrera P, et al. Treatment of refractory cholestatic pruritus with molecular adsorbent recirculating system (MARS). Transplant Proc 2006; 38:2511-2513. Another report describing the safe and efficient use of MARS in refractory pruritus.
58. Parés A, Cisneros L, Salmerón JM, et al. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2004; 99:1105-1110.
59. Bachli EB, Schuepbach RA, Maggiorini M, et al. Artificial liver support with the molecular adsorbent recirculating system: activation of coagulation and bleeding complications. Liver Int 2007; 27:475-484. The description of a negative patient selection unsuitable for extracorporeal treatment because of a high risk of bleeding.
60. Faybik P, Bacher A, Kozek-Langenecker SA, et al. Molecular adsorbent recirculating system and hemostasis in patients at high risk of bleeding: an observational study. Crit Care 2006; 10:R24. A thorough analysis of coagulation status in MARS patients using thrombelastography. This paper sheds light on the coagulation disorders of liver failure and helps steer anticoagulation in MARS patients.
61. Tan HK, Yang WS, Chow P, et al. Anticoagulation minimization is safe and effective in albumin liver dialysis using the molecular adsorbent recirculating system. Artif Organs 2007; 31:193-199.
62. Mitzner S. Anticoagulation in liver support. Liver Int 2007 (in press).
63. Hessel FP. Economic evaluation of the artificial liver support system MARS in patients with acute-on-chronic liver failure. Cost Effectiveness & Resource Allocation 2006; 4:16. The largest health ecomonic study on MARS in AoCLF. It reports a 3-year follow-up for survival and cost differences between MARS and standard of care.
64. Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA 2003; 289:217-222.
65. Mitzner S, Klammt S, Stange J, Schmidt R. Albumin regeneration in liver support-comparison of different methods. Ther Apher Dial 2006; 10:108-117. A systematic comparison between the currently known albumin-regenerating liver support methods.
66. Vienken J, Christmann H. How can liver toxins be removed? Filtration and adsorption with the Prometheus system. Ther Apher Dial 2006; 10:125-131. A technical description of the Prometheus system.
67. Rifai K, Manns MP. Review article: clinical experience with Prometheus. Ther Apher Dial 2006; 10:132-137. The first clinical case series published on the use of Prometheus in AoCLF.
68. Krisper P, Stauber RE. Technology insight: artificial extracorporeal liver support: how does Prometheus compare with MARS? Nat Clin Pract Nephrol 2007; 3:267-276. A comparison of current literature reports about Prometheus and MARS.
69. Evenepoel P, Laleman W, Wilmer A, et al. Prometheus versus molecular adsorbents recirculating system: comparison of efficiency in two different liver detoxification devices. Artif Organs 2006; 30:276-284. A comparison of substance clearance data of Prometheus and MARS.
70. Rifai K, Ernst T, Kretschmer U, et al. Removal selectivity of Prometheus: a new extracorporeal liver support device. World J Gastroenterol 2006; 12:940-944.
71. Evenepoel P, Meijers B, Verhamme P, et al. Fractionated plasma separation and adsorption in acute-on-chronic liver failure patients results in loss of pro and anticoagulant factors. Am J Transplant 2007 (in press).
72. Berry PA, Wendon JA. The management of severe alcoholic liver disease and variceal bleeding in the intensive care unit. Curr Opin Crit Care 2006; 12:171-177.
73. Chiu A, Fan ST. MARS in the treatment of liver failure: controversies and evidence. Int J Artif Organs 2006; 29:660-667.
74. Karvellas CJ, Gibney N, Kutsogiannis D, et al. Bench-to-bedside review: current evidence for extracorporeal albumin dialysis systems in liver failure. Crit Care 2007; 11:215.
75. Laleman W, Wilmer A, Evenepoel P, et al. Review article: Nonbiological liver support in liver failure. Aliment Pharmacol Ther 2006; 23:351-363.
76. Moreau R, Lebrec D. Diagnosis and treatment of acute renal failure in patients with cirrhosis. Best Pract Res Clin Gastroenterol 2007; 21:111-123. A current review putting MARS into the context of other HRS therapies.
77. Nalesso F, Brendolan A, Crepaldi C, et al. Albumin dialysis and plasma filtration adsorption dialysis system. Contrib Nephrol 2007; 156:411-418.
78. Oettl K, Stauber RE. Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. Br J Pharmacol 2007; 30 April 2007 [E-pub ahead of print]. An interesting paper that might open the door for additional therapeutic moves with regard to albumin regeneration in liver failure.
79. O'Grady J. Personal view: Current role of artificial liver support devices. Aliment Pharmacol Ther 2006; 23:1549-1557.
80. Saliba F. The molecular adsorbent recirculating system (MARS) in the intensive care unit: a rescue therapy for patients with hepatic failure. Crit Care 2006; 10:118. A current review on MARS as a bridging tool to liver transplantation from the principle investigator of the large French MARS trial in ALF.
81. Santoro A, Mancini E, Ferramosca E, Faenza S. Liver support systems. Contrib Nephrol 2007; 156:396-404. A current review of historical and present liver support methods discussing the pros and cons of the different technologies available.
82. Subramanian RM, Kellum JA. Extracorporeal liver support: a continuing challenge. Crit Care 2007; 11:106.
83. Williams R. The elusive goal of liver support: quest for the Holy Grail. Clin Med 2006; 6:482-487.